Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease

J Clin Oncol. 2010 Jul 10;28(20):e337; author reply e338-9. doi: 10.1200/JCO.2010.28.2525. Epub 2010 May 17.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Female
  • Humans
  • Prognosis
  • Receptor, ErbB-2 / metabolism*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab